We are live on ! Find out more
ALZN icon

Alzamend Neuro

14 hedge funds and large institutions have $335K invested in Alzamend Neuro in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0.05% more ownership

Funds ownership: 0%0.06% (+0.05%)

36% less funds holding

Funds holding: 2214 (-8)

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

78% less capital invested

Capital invested by funds: $1.49M → $335K (-$1.16M)

Holders
14
Holders Change
-8
Holders Change %
-36.36%
% of All Funds
0.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
1
Closed
12
Calls
$79K
Puts
Net Calls
+$79K
Net Calls Change
+$59K
Name Holding Trade Value Shares
Change
Change in
Stake
XT
26
XTX Topco
Cayman Islands
-$3.08K -10 Closed
IWS
27
Insight Wealth Strategies
California
-$2.37K -7 Closed
IA
28
IFP Advisors
Florida
-$1.19K -4 Closed
Fidelity Investments
29
Fidelity Investments
Massachusetts
-$64
JP Morgan Chase
30
JP Morgan Chase
New York
-$12

ALZN Hedge Fund Activity: Q4 2023 in Review

14 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2023, worth a combined $335K — down 78% from $1.49M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ALZN and 4 opened new positions — a net loss of 8 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $30.6K. The largest seller was Vanguard Group, cutting an estimated $104K.

  • 14 institutional investors held Alzamend Neuro (ALZN) as of Q4 2023, down from 22 in Q3 2023.
  • Funds reported $335K of Alzamend Neuro stock for Q4 2023, down 78% quarter-over-quarter.
  • 4 funds opened new Alzamend Neuro positions in Q4 2023 and 12 closed out, a net change of -8 holders.
  • The largest Alzamend Neuro buyer in Q4 2023 was HRT Financial, an estimated $30.6K added.
  • The largest Alzamend Neuro seller in Q4 2023 was Vanguard Group, an estimated $104K sold.

Based on aggregated 13F filings for Q4 2023.